Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Loading network data...

Showing 5 of 5 trials

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Role: lead

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Role: lead

A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

Role: lead

A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment

Role: lead

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Role: lead

All 5 trials loaded